Advertisement

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size

  • Sabran J. Masoud
  • Janice B. Hu
  • Georgia M. Beasley
  • John H. StewartIV
  • Paul J. MoscaEmail author
Melanoma

Abstract

Background

Talimogene laherparepvec (T-VEC) is the first injectable oncolytic viral therapy approved for in-transit melanoma metastasis, with a reported overall response rate (ORR) of 25% and complete response rate (CRR) of 10%. To ascertain the role of patient selection on outcomes in routine practice, we evaluated the impact of patient, lesion, and treatment factors on clinical response.

Methods

Medical records were extracted for patients with recurrent stage IIIB–IV melanoma completing T-VEC at Duke University Medical Center between 1 January 2016 and 1 September 2018. Kaplan–Meier analysis assessed time to response and survival, while logistic regression measured associations of clinicopathologic status, lesion burden, T-VEC dosing, and use of prior and concurrent therapy with ORR and CRR.

Results

Of 27 patients, an objective response was observed in 11 (40.7%), including one patient with partial response (3.7%) and 10 with complete response (37.0%). Time to complete response and overall response was a median 22 weeks (95% confidence interval [CI] 2.0–41.9 weeks and 15.8–28.2 weeks, respectively), and median progression-free survival was 17 weeks (95% CI 0–36 weeks). Logistic regression demonstrated each millimeter increase in maximum lesion diameter predicted decreased ORR (odds ratio [OR] 0.866, 95% CI 0.753–0.995; p = 0.04). Stage IV disease (OR 0.04, 95% CI 0.00–0.74; p = 0.031) and programmed death-1 inhibitor treatment (OR 0.06, 95% CI 0.01–0.74; p = 0.028) also predicted reduced clinical response.

Conclusions

This study corroborates recent data suggesting response rates to T-VEC may be higher than reported in clinical trials, arising in part from patient selection. T-VEC lesion diameter was persistently associated with clinical response and is a readily assessed predictor of successful T-VEC therapy.

Notes

Authors’ Contribution

GB, PM, and JS were responsible for treating patients and recording clinical experiences in electronic medical records. SM and JH conducted a review of medical records, conducted data analysis, and prepared this manuscript.

Disclosures

JS served on the T-VEC Speaker’s Bureau, Amgen Inc., 2015–2018. SM and JH received travel funding from the Polka Dot Mama Melanoma Research Foundation to attend the 2019 Society of Surgical Oncology (SSO) National Conference and the SSO Regional Therapy Conference, respectively. There are no other relevant conflicts of interest to disclose in relation to the subject matter of this manuscript.

References

  1. 1.
    Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;23(21):4588–4590.CrossRefGoogle Scholar
  2. 2.
    Gershenwald JE, Scolyer RA, Hess KR. Melanoma of the skin. In: Amin MB, Edge S, Greene FL, Schilsky RL, Byrd DR, Gaspar LE, et al., editors. AJCC cancer staging manual. 8th ed. Springer; 2017.Google Scholar
  3. 3.
    Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12(8):587–596.CrossRefGoogle Scholar
  4. 4.
    Abbott AM, Zager JS. Locoregional therapies in melanoma. Surg Clin North Am. 2014;94(5):1003–1015.CrossRefGoogle Scholar
  5. 5.
    Bilsland AE, Spiliopoulou P, and Evans TRJ. Virotherapy: cancer gene therapy at last? [version 1; peer review: 2 approved]. F1000Res. 2016.  https://doi.org/10.12688/f1000research.8211.1.Google Scholar
  6. 6.
    Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.CrossRefGoogle Scholar
  7. 7.
    Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.CrossRefGoogle Scholar
  8. 8.
    Franke V, Berger D, Klop W, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int J Cancer. 2019;145(4):974–978.CrossRefGoogle Scholar
  9. 9.
    Perez M, Miura J, Naqvi S, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann Surg Oncol. 2018;25:3960–3965.CrossRefGoogle Scholar
  10. 10.
    Louie R, Perez M, Jajja M, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228(4):644–649.CrossRefGoogle Scholar
  11. 11.
    Wong J, Cagle L, Kopald K, Swisher S, Morton D. Natural history and selective management of in transit melanoma. J Surg Oncol. 1990;44:146–150.CrossRefGoogle Scholar
  12. 12.
    Balch C, Gershenwald J, Soong S. Final version of 2009 AJCC melanoma staging and clas-sification. J Clin Oncol. 2009;27:6199–6206.CrossRefGoogle Scholar
  13. 13.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.CrossRefGoogle Scholar
  14. 14.
    Perone JA, Farrow N, Tyler DS, Beasley GM. Contemporary approaches to in-transit melanoma. J Oncol Pract. 2018;14(5):292–300.CrossRefGoogle Scholar
  15. 15.
    Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119 e1110.CrossRefGoogle Scholar
  16. 16.
    Dummer R, Hoeller C, Gruter IP, Michielin O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol Immunother. 2017;66(6):683–695.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Sabran J. Masoud
    • 1
  • Janice B. Hu
    • 1
  • Georgia M. Beasley
    • 2
  • John H. StewartIV
    • 3
  • Paul J. Mosca
    • 2
    Email author
  1. 1.School of MedicineDuke UniversityDurhamUSA
  2. 2.Department of SurgeryDuke University Medical CenterDurhamUSA
  3. 3.Department of SurgeryUniversity of Illinois College of MedicineChicagoUSA

Personalised recommendations